NBME 22 Answers : Block 3 : #34 = The risk for hemorrhagic stroke from drug X ...

support the site ⋅ become a member ⋅ unscramble the egg

NBME 22 Answers ↦

nbme22/Block 3/Question#34 (24.9 difficulty score)
The risk for hemorrhagic stroke from drug X ...
Case-control study🔍
tags:

+4 upvote downvote
submitted by sunny(2),

unscramble the site ⋅ become a member ($36/month)

why is ihst not a csros tiaelcosn ?uvysre ... sncie we rae asnikg at a lruracatpi mite

drdoom As Aristotle once quipped, “A ‘single-point in time’ doth not a cross-sectional study make.” The design of a cross-sectional study would not define “ahead of time” two cohorts (two groups); said another way, a cross-sectional design would not “split people into two groups.” In the design of a cross-sectional study there is only “one group”, and then you ask all members of that group some question (“Do you have asthma?”). At the end of a cross-sectional study, the authors will be able to make a statement like this: “We called 10,000 phone numbers with area code 415 at random and asked ‘Do you take Drug X?’ 500 responded ‘I don’t know’, 633 responded ‘Yes’, and 8,867 responded ’No’.” +13

castlblack That is interesting. I think the question is phrased ambiguously. I interpreted the question stem to say that they called random people and sorted them into hemorrhagic stroke pts vs controls after the fact using an ORAL questionnaire. Therefore the question would be " Did you have a stroke?" Yes = 702 or no = 1376. And thus would be a cross-sectional study. I see now that the questionnaire must be paper and contacted from some unstated list of drug X recipients. +

+1 upvote downvote
submitted by fexx(9),

I got this wrong but Case contrOl (O for Odds ratio): compares group who has DISEASE vs no disease - trying to find out what caused it CohoRt (R for Relative risk): compares group with RISK FACTORS/ EXPOSURE vs no exposure - trying to figure out if they will develop disease

-1 upvote downvote
submitted by bubbles(60),

unscramble the site ⋅ become a member ($36/month)

..lanS-stccoreoo. dssetiu epcoram a rgopu fo ppeeol thwi hte eeasisd adn a ogpur of pelpeo towhitu hte ds.eseai m'I nto ures I rdntueadsn why uyo nca llca eeoplp ynadorml dna lcal thta a ctronlo .grpou aWth if amgon hseot eldcla ,yrnaoldm mseo fo meth veah aols dah hhicarrgome srstk?oe

impostersyndromel1000 this is one of those Qs where you just dont over think it and focus on your first point, that they are comparing a group with the disease vs (potentially) one without it. Thats what i took from it at least (sorry fi this is too late) +2

tiagob Why is not Cohort ? since it compares groups exposed to drug X? +

djinn Cohort studies determines end of disease and CC determines begins +2